GPRC5D-Targeted CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
J. Clin. Oncol 2023 Mar 07;[EPub Ahead of Print], J Xia, H Li, Z Yan, D Zhou, Y Wang, Y Qi, J Cao, D Li, H Cheng, W Sang, F Zhu, H Sun, W Chen, K Qi, D Yan, T Qiu, J Qiao, R Yao, Y Liu, X Wang, Y Zhang, S Peng, CH Huang, J Zheng, Z Li, AH Chang, K XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.